Navigation Links
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Date:12/12/2011

cardiac involvement, cardiogenic shock and left ventricular dysfunction have been associated with initiation of GLEEVEC. The condition was reported to be reversible with the administration of systemic steroids, circulatory support measures, and temporarily withholding GLEEVEC.

Bullous dermatologic reactions (eg, erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several postmarketing reports describe patients able to tolerate the reintroduction of GLEEVEC at a lower dose with or without concomitant corticosteroids or antihistamines following resolution or improvement of the bullous reaction.

Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with GLEEVEC. TSH levels should be closely monitored in such patients.

Consider potential toxicities—specifically liver, kidney, and cardiac toxicity—and immunosuppression from long-term use.

Fetal harm can occur when administered to a pregnant woman; therefore, women of childbearing potential should be advised to not become pregnant while taking GLEEVEC tablets and to avoid breast-feeding while taking GLEEVEC tablets because of the potential for serious adverse reactions in nursing infants. Sexually active female patients taking GLEEVEC should use adequate contraception. If the patient does become pregnant while taking GLEEVEC, the patient should be advised of the potential hazard to the fetus.

Growth retardation has been reported in children and pre-adolescents receiving GLEEVEC. The long-term effects of prolonged treatment with GLEEVEC on growth in children are unknown; therefore, monitoring of growth in children taking GLEEVEC is recommended.

Cases of tumor lysis syndrome (TLS), including fatal cases, have been reported. The patients at risk of TLS are those with tumors having a high proliferative rate or high t
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
(Date:10/20/2014)... Colo. , Oct. 20, 2014  Luoxis ... (NYSE MKT: AMPE), today announced that its academic ... clinical and research potential for its novel RedoxSYS ... potential (ORP) in the body in response to ... value of ORP as a clinical marker will ...
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
... - CytRx Corporation,(NASDAQ:CYTR) today announced positive results ... lead drug candidate,arimoclomol significantly accelerated the recovery ... rat model of stroke, even when,treatment was ... stroke was,induced. These data confirm and expand ...
... PARK, N.C.--(BUSINESS WIRE)--Apr 3, 2007 -,Icagen, Inc. (NASDAQ: ... the independent Data Monitoring Committee,("DMC") of the Company's ... of sickle cell disease in adults, the,DMC recommended ... low,probability of achieving a reduction in crisis rate, ...
Cached Medicine Technology:CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 2CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 3CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 4CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies 5Icagen Terminates Phase III ASSERT Study 2Icagen Terminates Phase III ASSERT Study 3
(Date:10/20/2014)... October 20, 2014 Women’s health specialist, ... Obstetrics & Gynecology of Columbus, Inc., A Division of ... services to more than 100,000 patients annually. Dr. Murphy ... ages and stages of a women’s life. She is ... in Westerville and Dublin. , Dr. Murphy offers ...
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... October 20, 2014 JZ Fitness, an ... coaching, corporate wellness programming, authorship, international lecturing and community ... to announce the release of the JZ Fitness nutrition ... years of coaching thousands of individuals on nutrition, Jenn ... that does not require calorie counting or cumbersome food ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
... guideline on colorectal cancer screening released today by ... health care organizations, including the American College of ... (ASGE) and the American Cancer Society (ACS), offers ... and states a strong preference for screening tests ...
... National Naval Medical Center in Bethesda, Maryland Coincides, With Sleep ... ... Awareness Week, DALLAS, March 6 /PRNewswire/ - The ... importance for Dr. Keith Thornton,third-generation Dallas dentist and recognized expert on the ...
... Centers, Inc.,("GNC" or the "Company"), the largest global ... results for the,quarter and year ended Dec. 31, ... indirect wholly-owned subsidiary,of GNC Parent LLC, which was ... Management LLC and Ontario Teachers, Pension Plan Board. ...
... CARLSBAD, Calif., March 6 Genoptix, Inc.,(Nasdaq: GXDX ... participation in the Cowen and Company 28th Annual Health,Care ... Boston, Mass.,March 17 - 20, 2008., Dr. Tina ... COO, will present at the conference on Monday, March ...
... Quarterly Revenue and Returns to Profitability ... First Half 2008 Financial Guidance ... Time, NASHUA, N.H., March 6 iCAD, Inc. (Nasdaq:,ICAD), ... detection of cancer, today announced financial,results for the fourth quarter ...
... Adjusted EBITDA up 33%, TORONTO, March 6 /PRNewswire-FirstCall/ ... of products and services to the global life,sciences markets, ... MDS reported net revenues of $296 million, net income ... of $0.14.,Adjusted EBITDA rose to $40 million, up from ...
Cached Medicine News:Health News:New guidelines update recommendations on colorectal cancer screening 2Health News:New guidelines update recommendations on colorectal cancer screening 3Health News:New guidelines update recommendations on colorectal cancer screening 4Health News:Dallas Dentist Trains Navy Dentists on New Therapy to Treat Snoring and Obstructive Sleep Apnea 2Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 2Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 3Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 4Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 5Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 6Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 7Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 8Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 9Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 10Health News:General Nutrition Centers, Inc. Reports Fourth Quarter and Full Year 2007 Results 11Health News:Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference 2Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:iCAD Reports Fourth Quarter and Full Year 2007 Financial Results 9Health News:MDS Reports First Quarter 2008 Results 2Health News:MDS Reports First Quarter 2008 Results 3Health News:MDS Reports First Quarter 2008 Results 4Health News:MDS Reports First Quarter 2008 Results 5Health News:MDS Reports First Quarter 2008 Results 6Health News:MDS Reports First Quarter 2008 Results 7Health News:MDS Reports First Quarter 2008 Results 8Health News:MDS Reports First Quarter 2008 Results 9Health News:MDS Reports First Quarter 2008 Results 10Health News:MDS Reports First Quarter 2008 Results 11Health News:MDS Reports First Quarter 2008 Results 12Health News:MDS Reports First Quarter 2008 Results 13
... Vitatron T-series is a new top-line range ... bradycardia and Atrial Fibrillation (AF). Because the ... for AF, the treatment of AF is ... digital technology the heart rhythm is monitored ...
... Xper is the perfect partner for growing ... systems are scalable to meet your needs ... means that your Allura Xper FD20 system ... use. Openness to new technologies allows you ...
... MAX Cooling Power, Deeper Lesions ... arrhythmias, including atrial flutter, Freezor MAX is ... catheter with an 8mm ablation tip was ... is connected to the same cryoconsole as ...
... Volume coverage, not slices, changes the ... are performed. The LightSpeed VCT Series of ... making the imaging of difficult patients or ... groundbreaking technology opens the door to new ...
Medicine Products: